

Mainstay to Present at the Piper Jaffray Annual Healthcare Conference

DUBLIN--([BUSINESS WIRE](#))-- Regulatory News:

Mainstay Medical International plc (*Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE*) announces that its Chief Executive Officer, Peter Crosby, is scheduled to present at the Piper Jaffray Annual Healthcare Conference at 8:50 am ET on Tuesday, 2nd December, 2014. The conference is being held at The New York Palace Hotel, New York.

The live webcast will be accessible through the following link: <http://www.media-server.com/m/p/qhu38h5i>. The webcast replay will be available approximately 2 hours after the webcast presentation ends and can also be accessed through the above link for a period of one month.

The associated corporate presentation will be available on the Mainstay Medical website (www.mainstay-medical.com) from the time of commencement of Mr. Crosby's presentation for a period of one month (unless replaced during that period by an updated corporate presentation).

Mainstay is an Irish medical device company with operations in Ireland, Australia and the United States. The Company is focused on the development and commercialisation of ReActiv8, an innovative implantable neurostimulation device designed to treat people with debilitating Chronic Low Back Pain (CLBP) by helping to restore control to the muscles that stabilise the lumbar spine.

Clinical trials with ReActiv8 are ongoing in Europe and Australia, and several sites continue to enrol subjects. The purpose of the clinical trial is to investigate ReActiv8 as a treatment for adults with CLBP who have few other treatment options.

- End -

About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation medical device, ReActiv8, for people with CLBP. Low Back Pain is a leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments.

The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that stabilize the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spinal surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on economies.

Further information can be found at www.mainstay-medical.com

Contacts

Media queries:

Jonathan Neilan, FTI Consulting

Tel: +353 1 663 3686

Email: jonathan.neilan@fticonsulting.com

or

Jeanne Bariller, FTI Consulting (French language enquiries)

Tel: +33 1 47 03 6863 / +33 67 412 4452

Email: jeanne.bariller@fticonsulting.com

or

Investor relations:

Jillian Connell, The Trout Group LLC

Tel: +1 646 378 2956 / +1 617 309 8349

Email: jconnell@troutgroup.com

or

ESM Advisers:

Fergal Meegan / Barry Murphy, Davy

Tel: +353 1 6796363

Email: fergal.meegan@davy.ie /

barry.murphy2@davy.ie

Source: Mainstay Medical International plc